A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non–muscle-invasive bladder cancer

Sood, Rajeev; Sharma, Hitt; Sharma, Bhuvaneshwari; Parekh, Sameer; Pujari, Pramod; Shewale, Sunil

doi:10.1016/j.urolonc.2020.01.002

Cited by 11 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sixty-two studies [ 2 , 3 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76...…”

Section: Resultsunclassified

“…On the contrary, the remaining n = 27 [ 2 , 3 , 23 , 30 , 31 , 32 , 33 , 43 , 44 , 45 , 47 , 49 , 52 , 54 , 57 , 58 , 59 , 61 , 64 , 66 , 67 , 70 , 72 , 73 , 74 , 78 , 82 ] were dual or multi-treatment comparison analysis. The cumulative sample size for each study arm was directly associated with the study design with n = 79 [ 2 , 3 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ,…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis

Giudice

Asero

Bologna

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: In an era of Bacillus of Calmette-Guérin (BCG) shortages, the comparative efficacy from different adjuvant intravesical BCG strains in non-muscle invasive bladder cancer (NMIBC) has not been clearly elucidated. We aim to compare, through a systematic review and meta-analysis, the cumulative BC recurrence rates and the best efficacy profile of worldwide available BCG strains over the last forty years. Methods: PubMed, Scopus, Web of Science, Embase, and Cochrane databases were searched from 1982 up to 2022. A meta-analysis of pooled BC recurrence rates was stratified for studies with ≤3-y vs. >3-y recurrence-free survival (RFS) endpoints and the strain of BCG. Sensitivity analysis, sub-group analysis, and meta-regression were implemented to investigate the contribution of moderators to heterogeneity. A random-effect network meta-analysis was performed to compare BCG strains on a multi-treatment level. Results: In total, n = 62 series with n = 15,412 patients in n = 100 study arms and n = 10 different BCG strains were reviewed. BCG Tokyo 172 exhibited the lowest pooled BC recurrence rate among studies with ≤3-y RFS (0.22 (95%CI 0.16–0.28). No clinically relevant difference was noted among strains at >3-y RFS outcomes. Sub-group and meta-regression analyses highlighted the influence of NMIBC risk-group classification and previous intravesical treated categories. Out of the n = 11 studies with n = 7 BCG strains included in the network, BCG RIVM, Tice, and Tokyo 172 presented with the best-predicted probability for efficacy, yet no single strain was significantly superior to another in preventing BC recurrence risk. Conclusion: We did not identify a BCG stain providing a clinically significant lower BC recurrence rate. While these findings might discourage investment in future head-to-head randomized comparison, we were, however, able to highlight some potential enhanced benefits from the genetically different BCG RIVM, Tice, and Tokyo 172. This evidence would support the use of such strains for future BCG trials in NMIBCs.

show abstract

Section: Resultsunclassified

Section: Resultsmentioning

confidence: 99%

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis

Giudice

Asero

Bologna

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…There is not much literature available about the AEs of Moscow-I strain of BCG. One recent study comparing 80 mg and 120 mg of BCG Moscow-I did not show significant AEs [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)

Thyavihally

Dev

Waigankar

et al. 2022

Asian Journal of Urology

View full text Add to dashboard Cite

“…Therefore, by reducing or preventing the recurrence of superficial bladder cancer, both patients and health care systems can be helped. So far, many studies have been performed to compare the effect of different intravesical treatments on superficial bladder cancer [34][35][36][37][38][39] . However, it was difficult to compare these findings in terms of differences in the amounts of dosage and the variety of strains used in different brands.…”

Section: Intravesical Bcg Efficacy In Bladder Cancer Recurrencementioning

confidence: 99%

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma

Doroud

Hozouri

2022

IBJ

View full text Add to dashboard Cite

Bacterial products have attracted much attention as potential antitumor agents, with the ability to provide direct tumoricidal effects, leading to the inhibition of tumor growth. Treatment of superficial bladder cancer with intravesical BCG has a more reduction potential than surgery in tumor recurrence rate. BCG, the gold standard for NMIBC, is manufactured from different strains and produced commercially with varied strengths. There are a few countries known as the manufacturer of this strategic biopharmaceutical product, and Iran as a member of the Eastern Mediterranean Region plays a vital role in supplying this vaccine. Studies have failed to uncover the exact mechanism of action of the intravesical BCG; however, evidence points toward an immunogenic mechanism that proficiently modifies a biologic response and provokes the immune cells in order to kill and suppress tumors. Among various underlying mechanisms, BCG bacillus attachment to fibronectin through its FAP is a pivotal mechanism for BCG tumoricidal activity.

show abstract

A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non–muscle-invasive bladder cancer

Cited by 11 publications

References 20 publications

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis

Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma

Contact Info

Product

Resources

About